All News

One expert from the University of Colorado Cancer Center explains the multidisciplinary aspect of sarcoma care to maximize patients’ functioning.

Having a check-up appointment without receiving any type of scan is good, but also scares me.

From a TODAY contributor opening up about breast reconstruction surgery to Arizona rep. Raúl Grijalva completing cancer treatment, here’s what’s going on in the oncology space this week.

I was diagnosed with myeloma more than two decades ago and am lucky to have support throughout.

Results from a phase 2/3 study demonstrated that paxalisib led to a 3.8-month survival improvement in some patients with glioblastoma.

A novel intratumoral treatment was administered to the first patient in a phase 3 trial for certain patients with metastatic soft tissue sarcoma.

Side effects from multiple myeloma, such as six inches of collapsed vertebrae, have made me adjust my lifestyle, but I make the most of what I can.

Patients with favorable-risk prostate cancer “should be aware that they don't need treatment right away,” one expert said.

Whenever I received bad news regarding my colorectal cancer, I felt like it was the end — until my therapist told me something that changed everything.

During summer 2024, there have been many changes made in the non-small cell lung cancer and small cell lung cancer spaces. Here are four top news stories.

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

The TIL therapy OBX-115 ‘may have the potential to address’ an unmet need among patients with metastatic or locally advanced melanoma.

I spent a lot of time after my metastatic breast cancer diagnosis worrying of each experience would be my last. Then I had an epiphany.

The Food and Drug Administration granted a fast track designation to ADI-270, an off-the-shelf CAR-T cell therapy for clear cell renal cell carcinoma.

Perioperative treatment with BRAF and MEK inhibitors was found to benefit some patients with stage 3 and 4 melanoma, according to a recent study.

I was diagnosed with kidney cancer and pancreatic neuroendocrine tumors two years ago, but I’ve learned a lifetime of lessons since.

Oncology drug shortages may slow down the discovery of new cancer treatments, an expert from the NCCN explained.

Having two supportive nurse navigators by my side during breast cancer made my experience much easier, especially when I wanted mental or physical support.

Gina Young, B.S.N., RN, has extraordinary diversity in her knowledge and has a comprehensive understanding of the care required for patients with complex cases.

One expert explains how bispecific antibodies are a ‘targeted and effective’ option for patients with multiple myeloma.

During my "watch and wait" time for prostate cancer, I spend this time wisely on things like attending writing webinars.

Patients with TGCT are encouraged to honestly discuss their pain with their care teams.

One expert explains the importance of a multidisciplinary care team for patients with TGCT.

TGCT is a non-malignant tumor, but one expert explained how it can similarly affect patients.

Tenosynovial giant cell tumors are not malignant but can impact patients’ quality of life, as one expert explained.

Systemic therapy and active surveillance can be viable options for patients with TGCT, as one expert explained.

While I was receiving treatment for endometrial cancer, I received so much support from friends, coworkers and people from my church.

My wife faced ovarian cancer, breast cancer and multifocal motor neuropathy, and I was her only caregiver.